Breast Cancer Clinical Trial
Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer
Summary
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) using ferumoxtran-10, may help find and diagnose breast cancer that may have spread to the axillary lymph nodes and may help in planning breast cancer treatment.
PURPOSE: This phase II trial is studying how well MRI using ferumoxtran-10 works in finding metastases to the axillary lymph nodes in patients with invasive breast cancer.
Full Description
OBJECTIVES:
Primary
Determine the utility of magnetic resonance (MR) imaging using ferumoxtran-10 in identifying metastases to the axillary lymph nodes in patients with invasive breast cancer.
Secondary
Determine the changes in MR T1 and T2 signal intensity in primary breast tumors after administration of this drug to these patients.
Determine the potential of delayed imaging, in terms of defining tumor boundaries, in these patients.
OUTLINE: Patients receive ferumoxtran-10 IV over 25-30 minutes on day 0 in the absence of unacceptable toxicity. Patients undergo MRI of the involved breast and ipsilateral axilla on day 0 (once before and once after ferumoxtran-10 administration) and then once on day 1.
Within 3 weeks after the completion of imaging studies, patients undergo sentinel lymph node biopsy. If the sentinel node is positive for malignancy on touch prep, an axillary lymph node dissection is performed if clinically indicated.
Patients are followed at approximately 1 month after surgery.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 8.3 months.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed invasive breast cancer
Candidate for sentinel lymph node biopsy and/or axillary lymph node dissection
Hormone receptor status:
Not specified
PATIENT CHARACTERISTICS:
Age
18 and over
Sex
Male or female
Menopausal status
Not specified
Performance status
Not specified
Life expectancy
Not specified
Hematopoietic
WBC ≥ 3,000/mm^3
Absolute neutrophil count ≥ 1,500/mm^3
Platelet count > 100,000/mm^3
Ferritin ≤ 350 ng/mL*
Transferrin saturation level ≤ 40%* NOTE: *Patients with lab values above these limits may be eligible provided there is no hemochromatosis by hematology consultation
Hepatic
Bilirubin normal
AST and ALT ≤ 2.5 times upper limit of normal
Alkaline phosphatase normal
PT normal
Albumin normal
No history of cirrhosis
Renal
Creatinine normal OR
Creatinine clearance > 60 mL/min
Cardiovascular
No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmia
Other
Not pregnant or nursing
Negative pregnancy test
Medically stable
No ongoing or active infection
No history of allergic reaction attributed to compounds of similar chemical or biological composition to ferumoxtran-10 (e.g., iron preparations, parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations)
No history of allergic reaction to any contrast media
No immunodeficiency that would predispose patient to a specific or non-specific mediator release
No contraindication to MRI, including any of the following:
Severe claustrophobia
Pacemaker
Aneurysm clips
Defibrillators
Certain types of replacement joints
Other institutional contraindication to MRI
No psychiatric illness or social situation that would preclude study compliance
No other uncontrolled illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
Not specified
Chemotherapy
Not specified
Endocrine therapy
Not specified
Radiotherapy
Not specified
Surgery
Not specified
Other
More than 30 days since prior investigational agents
More than 3 months since prior ferumoxides
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Richmond Virginia, 23298, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.